Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer

Table 1 Characteristics of the Study Population

Characteristic	Patients, No. (SD/%)^a,b N = 66
Clinical characteristics
Age, mean (SD), y	52 (9)
Dose, mg/m², median^c
T1: anthracycline, 440	54 (82)
T1: trastuzumab, 1560	31 (47)
T2: anthracycline, 445	66 (100)
T2: trastuzumab, 2440	66 (100)
Risk factors
Cardiovascular risk factors	31 (47)
Hypertension	13 (20)
Diabetes mellitus	3 (5)
Hyperlipidemia	12 (18)
Family history of premature CAD	4 (6)
Smoking history	13 (20)
Radiotherapy	50 (76)
Heart rate, baseline echocardiogram, mean (SD), bpm	71 (12)
Cardiotoxicity (a decrease ≥10% to EF ≤53%)	13 (20)

Abbreviations: bpm beats per minute, CAD coronary artery disease, EF ejection fraction, T0 baseline (pretreatment), T1 time from start of chemotherapy to first echocardiogram (median, 2.85 months), T2 time from start of chemotherapy to second echocardiogram (median, 5.44 [4.61-6.47] months)
^aUnless otherwise indicated
^bData are expressed as value (%) for categorical data and mean (SD) for continuous data
^cT1: 2.25 (median) months from the start of chemotherapy to the first echocardiogram; T2: 5.44 (4.61-6.47) months from the start of chemotherapy to the second echocardiogram

ISSN: 1471-2407